Jerry L. Spivak, MD, discusses treating patients with polycythemia vera, which is a type of myeloproliferative neoplasm that can often derive from essential thrombocythemia, particularly among women.
Jerry L. Spivak, MD, director of the Center for the Chronic Myeloproliferative Disorders and professor of Medicine and Oncology at the Johns Hopkins University School of Medicine, discusses his key takeaway from his presentation from the Texas Virtual Myeloproliferative Neoplasm Workshop regarding treating patients with polycythemia vera (PV), which is a type of myeloproliferative neoplasm that can often derive from essential thrombocythemia (ET), particularly among women.
To do the most good for these patients, it is best to stick with the simplest treatment, says Spivak. In patients with no symptoms, it is not as important to reduce the white blood cell or platelet counts.
Women are more at risk for PV compared with men, and they are more likely to have progressed to PV from ET than they are to progress to myelofibrosis from ET. In this case, they are expected to have a good lifespan, Spivak says. However, it is important that patients who are asymptomatic be left alone.
<<View more resources and information from the Texas Virtual MPN Workshop
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More